Money laundering. Hospitals & clinics buy drugs at lower prices from drug company but sell them to patients/insurance at much higher prices, keeping difference to pay own costs (instead of directly charging more for their services). nbcnews.com/nbc-out/out-he…
This is essentially money laundering. The public gets the impression that the clinic/hospital costs are lower & that drugs are much higher. The trouble is that eventually such drugs go generic, ending the scam.
Clinics that have been marking up HIV drugs for years are now shutting down as those drugs go generic. They would have to charge full price for their services to stay open but seems insurance won’t pay those rates.
Now you might think that such a money laundering scam would be illegal. But it’s not. It’s working as intended. The federal gov’t calls this 340b. It was designed to help hospitals & clinics tack their expenses onto drugs that they bought at discounts.
Patients were never told that their drugs were actually being sold by drug companies for lower prices but then marked up. This is a case of price distortion, along with rebates and copay maximizers. Makes drug list prices go sky high and grow- that’s what public sees.
At this point, around 30-50% of list price a patient pays for a drug goes to some middleman, not the drug company. The net prices drug companies get are lower, have been flat for last 5 years (below inflation). What’s next? Might congress jam its lunch bill into drug costs?
Why not? Free lunch for Washington, patients pay more thanks to shoddy insurance system, & of course drug industry takes heat for rising list prices.
Hospitals & clinics shouldn’t be a part of this problem. They should pass drug costs through, insurance should pay for drugs what drugs costs and for services what services costs.
End 340b. Lower OOP costs. And let’s celebrate when drugs go generic instead of marveling at the stupidity of a system that would have HIV clinics shut down when a medicine they dispense becomes much less expensive.
But no, says Congress. Let’s blame it on people who developed the medicines. Let’s cut incentives for further innovation. Then let’s set up our re-election headquarters in the empty shell left behind by that HIV clinic.
This mess is complicated but it’s not too complex to fix. Check out nopatientleftbehind.org @NPLB_org especially be sure to check out the explainers under “Policy—>Our Presentations” if you want to leave more about how healthcare works and what should be done to fix it.
Oh, laundering of hospital expenses through inflated drug prices doesn’t even end once a drug goes generic. Hospitals mark up generics like crazy to make their services seem cheaper. If hospitals were restaurants, drugs would be the wine. bloomberg.com/news/articles/…
But don’t think we can just cut drug markups to save money. While drugs aren’t THAT expensive (as wine isn’t really $100/bottle), if hospitals can’t mark up drugs, they would just charge what they must for surgery… as they should, so payers can compare & reward efficiency.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Peter Kolchinsky

Peter Kolchinsky Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @PeterKolchinsky

16 Jun
If best of biopharma industry were incarnated, would be as my friend Paul Hastings @phastings14, CEO of Nkarta, now Chair of BIO @IAmBiotech, & a good soul. Here’s his story & call for reforms: Lower OOP & make drugs go generic w/o undue delays. @NPLB_org vimeo.com/octo8er/review…
What Paul speaks to is very much aligned with the reforms supported by No Patient Left Behind (nopatientleftbehind.org), an organization I helped start and of which Paul is a personal supporter (see Life Science Builder page), as my firm and I support BIO. 2/8
Paul’s comments will make rent-seekers in our industry uncomfortable (companies that have gotten good at milking old drugs for high profits as if they still merit more reward for having been recently invented). Still, I know many within those companies who agree with Paul. 3/8
Read 8 tweets
7 May
Some think patents stand in way of making more vaccines. They don’t. Skill & money do. Just as most of us couldn’t replicate Mona Lisa (no IP there), few can make advanced vaccines. Vaccine companies have already partnered w/ all skilled producers they could find to make doses.
The reason they have already liberally partnered is b/c incentives were there to do so & competition among companies spurred them to get to market first. All those big contracts offered enough reward that innovators shared their knowledge & reward w/ manufacturing partners.
Anyone who didn’t partner with others to expand manufacturing knew that other companies would to sell more doses first, shrinking market for others (especially since wasn’t always evident there would be a long term booster market for laggards).
Read 18 tweets
26 Apr
This Nature paper makes strong case that any COVID, not just serious disease & hospitalization, jacks up risk of many health problems for many months thereafter (long COVID). What’s it mean for vaccines? Durably high protection matters, & boosters. nature.com/articles/s4158…
More specifically, it means that when you hear about vaccines that protect by 70% but claim “yeah, but protects 100% against severe diseases”, know that the 30% residual risk of getting even mild-moderate COVID comes with more risk than we thought. It’s risk worth avoiding.
So right now, get whatever vaccine you can. mRNA seems better than adenoviral and inactivated vaccines. Get booster when offered, both to protect against new variants & old ones, b/c immunity wanes.
Read 14 tweets
28 Mar
Do patient groups perceive drug price controls (HR3) will end progress in treatment of many diseases? Cancer, Alzheimer’s, Parkinson’s... done. HR3 not benign. Price controls always kill investment in risky R&D. No “alternative” economics on that point. timmermanreport.com/2021/03/a-glim…
Some patient advocacy groups I’ve spoken with say “we don’t want to be seen defending drug industry”. And yet, as w/COVID, that’s who develops the treatments- that’s where hope comes from. What’s the point of having standing and pathos if you won’t use it to defend what’s right?
Some say “no, NIH invents drugs.”. They misunderstand. NIH builds foundation but not the product. It makes prototypes at best. But it’s takes the $160B of R&D each year to bring ~50 drugs/year to market... to patients. nopatientleftbehind.docsend.com/view/mxht62ee3…
Read 11 tweets
28 Mar
Everything wrong w/ healthcare & drug pricing debate is evident in these slide. Healthcare costs in Massachusetts grew at 4.3% (slide 32). On 33, they report drug spending grew 7.2% gross of rebates. On 34, they show it’s only 3% growth net of rebates. mass.gov/doc/presentati…
Conclusion on slide 55 blames drug prices for Medicare spending growth, yet in footnote acknowledge its “not net of rebates”. Well why not? They clear know net drug spending growth is lower than almost every other aspect of healthcare. It’s clearly hospitals driving growth.
They talk about hospitals, but highlighting drugs is willful misdirection. As for patients’ costs, slide 42 & 47 shows shift towards higher out of pocket costs. So even as drug spending shrinks as a fraction of healthcare spending, Americans afford less & blaming drug costs.
Read 8 tweets
3 Mar
Last Call! Apply by Thu March 4th for Spring 2021 “Business of Biotech” discussion sessions (Wed, 3-5pm ET, March 10/17/24). If can’t make it, our virtual Thinkific materials (listed below) are available indefinitely & more discussions to come. Register at racap.com/courses
RA Capital hosts course b/c we are inspired by all that we've seen the biotech industry accomplish for human health, have learned a lot of the past couple of decades, and want to share lessons learned so that biotech can be even better than it has been.
And now more than ever, we think it's important for everyone in biotech to understand and unite around Biotech Social Contract that governs what the public expects of innovators and insurance.
Read 25 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(